Clinical Investigation of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified NK92 Cells in Relapsed and/or Refractory Acute Myeloid Leukemias
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Anti-CD33 CAR NK92 cell therapy PersonGen Biomedicine (Primary)
- Indications Myeloid leukaemia
- Focus Adverse reactions
- Sponsors PersonGen Biomedicine
- 07 Nov 2016 New trial record